Press Room

The Charcot-Marie-Tooth Association today welcomed Craig Zeltsar, principal and co-founder of NNE Marketing, LLC, to its Board of Directors.

ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.

The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).

What is CMT1A? Type1ACMT1A is the most common form of Charcot-Marie-Tooth, comprising around 66 percent of all patients with CMT Type 1. The disease is caused by a duplication of the PMP22 gene on Chromosome 17. ...